Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke by Zhao, Lian et al.
Page 1 of 15  
EFFECT OF ASPIRIN, CLOPIDOGREL AND DIPYRIDAMOLE ON SOLUBLE 
MARKERS OF VASCULAR FUNCTION IN NORMAL VOLUNTEERS AND PATIENTS 
WITH PRIOR ISCHAEMIC STROKE 
 
Lian Zhao,1,2 Laura Gray,1,2 Jo Leonardi-Bee,1,2 Chris S Weaver,1,2 Stan Heptinstall,2 
Philip M W Bath1,2  
 
Institutes of Neuroscience1 & Clinical Research,2 University of Nottingham, Nottingham 
UK 
 
Correspondence: Professor Philip Bath 
Division of Stroke Medicine 
University of Nottingham 
Queen’s Medical Centre 
Nottingham NG7 2UH 
 
Tel: 0115 970 9348 
Fax: 0115 875 4506 
Email: philip.bath@nottingham.ac.uk 
 
Keywords: aspirin, clopidogrel, dipyridamole, leucocyte, platelet, stroke 
 
Page 2 of 15  
 
Although the mechanisms of action by which aspirin, clopidogrel and dipyridamole 
inhibit platelets are well characterised, their effects on soluble modulators of 
thrombosis, inflammation, and endothelial function have yet to assessed 
systematically. In this investigation aspirin (A), clopidogrel (C), and dipyridamole (D) 
were administered singly and in combination (A, C, D, AC, AD, CD, ACD) in random 
order for two weeks (without washout) to 11 healthy subjects and 11 patients with 
previous ischaemic stroke. At the end of each treatment period plasma cyclic 
guanosine monophosphate (cGMP), monocyte chemoattractant pertide-1 (MCP-1), 
nitric oxide metabolites (NOx), plasminogen activator inhibitor-1 (PAI-1) and von 
Willebrand factor (vWf); and serum C-reactive protein (CRP) and platelet derived 
growth factor (PDGF); were measured blinded to treatment. Dipyridamole reduced 
plasma vWf levels (%) in both volunteers, -10.0 (5.0), and patients, -10.1 (4.3) 
(p<0.05). Dipyridamole also lowered CRP (mg/L) in patients, -0.96 (0.47), but not 
volunteers. Clopidogrel reduced PAI-1 (ng/mL) in volunteers, -5.30 (2.20) (p<0.05), 
and patients, -3.61 (2.75) (non-significant trend). Aspirin lowered PDGF (ng/mL) in 
volunteers, -3.46 (1.55) (p<0.05), but not patients. Triple antiplatelet therapy was 
superior to dual and mono therapy in reducing vWf levels. In conclusion, antiplatelet 
agents have non-platelet-related effects on soluble modulators of thrombosis, 
inflammation, and endothelial function. In particular, dipyridamole reduces plasma 
vWf and clopidogrel lowers plasma PAI-1 levels. These effects may explain, in part, 
their roles in preventing atherothrombogenesis. 
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INTRODUCTION 
 
The three antiplatelet agents, aspirin, clopidogrel and dipyridamole, are widely used 
for secondary stroke prevention on the basis of results from large trials and 
systematic reviews.1, 2 Whilst their antiplatelet actions are well described, their effects 
on other vascular cells and soluble factors are less well defined. 
 
Platelets, leucocytes, and endothelial cells contribute to the pathogenesis of vascular 
disease3  through direct cell-cell interactions and the release of atherothrombogenic 
factors. Platelets release several cytokines including platelet-derived growth factor 
(PDGF), platelet factor 4 and CD40 ligand, each of which has been linked to the 
inflammation and coagulation pathways.4-6 Similarly, monocytes and macrophages 
generate cytokines including macrophage chemoattractant protein-1 (MCP-1), a 
chemokine important during atherogenesis,7 and interleukin-6 (IL-6),8 a procoagulant 
and stimulator of hepatic synthesis of C-reactive protein (CRP); CRP amplifies 
inflammatory and procoagulant responses.9,10 IL-6 also increases endothelial 
production of the fibrinolytic inhibitor, plasminogen activator inhibitor type 1 (PAI-1).3, 
11 Endothelial cells also release von Willebrand factor (vWf), which facilitates platelet 
and thrombus adhesion to endothelium,12 and nitric oxide (NO), a potent 
vasorelaxant, antiplatelet and antileucocyte agent 13 whose effects are mediated by 
the second messenger cyclic guanosine monophosphate (cGMP).14 
 
We assessed the effects of aspirin, clopidogrel and dipyridamole on a panel of the 
above soluble markers of vascular function in normal volunteers and patients with a 
prior history of ischaemic stroke. We also assessed the effect of combining the three 
antiplatelet agents on the soluble markers since we have shown previously that three 
drugs may be superior to one or two in inhibiting platelet function in vitro.15 
Page 4 of 15  
METHODS 
 
Design 
Two randomised, outcome-blinded, multiway, crossover trials of antiplatelet therapy 
were performed in normal volunteers and patients with prior ischaemic stroke. The 
study design has been published previously 16 in a report of the effect of aspirin, 
clopidogrel and dipyridamole on the function of circulating platelets, phagocytes and 
their conjugates. 
 
Subjects 
The study protocol was approved by the local Research Ethics Committee. All subjects 
gave written informed consent and the trials were performed according to the 
Declaration of Helsinki and the principles of Good Clinical Practice. Eleven healthy 
volunteers without any history of vascular disease were recruited from hospital or 
university staff or their friends. Eleven stable patients with a prior history of ischaemic 
stroke (on clinical and neuroimaging criteria) within 5 years were recruited from the 
stroke service at Nottingham City Hospital;16 each patient was receiving aspirin for 
vascular prophylaxis. Subjects were excluded if they had a history of cerebral 
haemorrhage, gastrointestinal bleeding, peptic ulcer, anaemia, thrombocytopenia, any 
severe concomitant medical condition, or hypersensitivity or intolerance to any of the 
study drugs; were taking anticoagulation or a non-steroidal anti-inflammatory drug; 
had a blood pressure > 180/110 mmHg; or were pregnant or lactating women. 
 
Interventions 
All subjects received two-week periods of open-label aspirin (A, 75mg daily), 
clopidogrel (C, 75mg daily) or modified release dipyridamole (D, 200mg twice daily). 
The drugs were given either singly (A, C, or D), in pairs (AC, AD, or CD) or all three 
together (ACD) in random order.16 Normal volunteers, but not patients, were also 
studied off all therapy. No washout periods were used since the length of each 
treatment phase (14 days) exceeded the lifespan of platelets (~10 days); further, it 
would have been inappropriate to deprive patients of antiplatelet therapy during such 
periods. Randomisation was performed using a computer and the treatment codes 
held by the hospital’s Pharmacy to ensure concealment of allocation. Blood samples 
were collected at the end of each two-week treatment phase. Adverse events are 
reported previously.16 Subjects who withdrew from treatment were replaced to ensure 
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that complete data were present for each person; laboratory data from withdrawing 
subjects are not included in the statistical analyses. 
 
Laboratory study 
Serum and plasma collected into 3.8% sodium citrate (1:9 volume) or 4.0 mmol/L 
EDTA were centrifuged (1,500g for 15min) within 1 hour of venepuncture. Aliquots 
were frozen at –80oC and then assayed in batches using commercially available ELISA 
kits. CRP (high sensitivity kit, Kalon Biological, Hants, UK) and PDGF (R&D System, 
Abington, UK) were measured in serum; cGMP (R&D System), vWf (Corgenix, 
Cambridgeshire, UK), MCP-1 (R&D System) and PAI-1 (Technoclone TC, Surrey, UK) 
were analysed in citrated plasma. 
 
Plasma (citrated) nitric oxide (NOx) levels were determined from measurement of its 
stable end products, nitrate and nitrite, by a chemiluminescence (Sievers 280 Nitric 
Oxide Analyser, Analytix Limited, County Durham, UK) method.17 This involved 
injecting 10µL of deproteinised plasma samples into vanadium chloride.18 The nitrate 
and nitrite present in samples were reduced to NO, and quantified from a calibration 
curve based on prepared concentrations of sodium nitrate. 
 
Statistical analysis 
The primary analysis compared the presence and absence of each drug on soluble 
markers, i.e. aspirin versus no aspirin, clopidogrel versus no clopidogrel, and 
dipyridamole versus no dipyridamole. Secondary analyses compared triple therapy 
(ACD) versus all other drugs, as before.16 Analyses were performed using the SAS 
statistical package. 
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RESULTS 
 
Demographic and clinical information for the subjects are given in table 1. The stroke 
patients are representative of our clinical stroke service and were significantly older 
and had more risk factors (more hypertension and smokers, higher systolic blood 
pressure, and elevated total cholesterol) than the volunteers (all p<0.05). 
 
When considering the individual effects of the three antiplatelet agents on soluble 
markers of vascular function, three observations were made. First, dipyridamole 
significantly reduced plasma vWf levels in both volunteers and stroke patients (table 
2). Second, dipyridamole significantly reduced serum CRP in patients but not 
volunteers (where a non-significant increase was seen). Third, clopidogrel reduced 
plasma PAI-1 concentrations in volunteers (significant) and patients (non-significant 
trend). Fourth, aspirin significantly reduced serum PDGF levels in volunteers but not 
patients. The three antiplatelet agents did not appear to alter MCP-1, NOx or cGMP 
levels in either subject group. 
 
Patients had significantly lower levels of plasma NOx (difference 0.37, SD 0.17, 
p<0.001) and higher levels of plasma vWf (difference -43.1, SD 39.5, p=0.019) than 
volunteers (table 3); no differences in the other biomarkers were apparent. The use of 
triple antiplatelet therapy was not superior to mono or dual therapy with the exception 
that the combination of all three agents was associated with significantly lower levels 
of plasma vWf than dual aspirin and clopidogrel in both volunteers and patients (table 
3), a finding compatible with the above observation that dipyridamole lowers vWf 
levels. 
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DISCUSSION 
 
These studies show that antiplatelet agents may alter soluble markers of vascular 
function. In particular, dipyridamole significantly reduced plasma vWf levels in both 
volunteers and patients with previous stroke, an effect seen previously in an 
independent study involving patients with ischaemic heart disease.19 
 
Studies in vitro and ex vivo have found that dipyridamole significantly reduces platelet 
adhesion to vascular sub-endothelium although the mechanism remains unclear.20, 21 
Both vWf and P-selectin are stored in Weibel-Palade body in the endothelium.22, 23 Pro-
inflammatory mediators activate cells causing Weibel-Palade bodies to fuse with the 
cell membrane resulting in the release of vWf and surface exposure of P-selectin. vWf 
and P-selectin are the primary molecules involved with platelet interaction with 
endothelium.23, 24 In the present study we provide evidence that the inhibitory effect 
of dipyridamole on platelet adhesion may be mediated in part through inhibition of 
vWf release from endothelial cells. 
 
Dipyridamole also appeared to lower serum CRP levels, a previously unreported 
finding. However, this finding was only present in patients with prior cerebrovascular 
disease and could simply reflect chance. Several studies reported that dipyridamole 
potentiates NO-induced vasodilator activity through inhibiting phosphodiesterase V 
activity and thereby enhancing intracellular cGMP levels.25-27 However, we did not 
observe changes in plasma NOx and cGMP levels with dipyridamole. 
 
Clopidogrel showed an inhibitory effect on plasma PAI-1 levels (significant in 
volunteers, non-significant in patients) but not on other biomarkers. The reduction of 
PAI-1 has been observed in two earlier studies 28, 29 and may be achieved partially 
through inhibition of platelet activity.30, 31 Previous studies reported that clopidogrel 
lowers CRP levels in patients with acute vascular disease.32-34 However, we did not 
confirm this observation, perhaps because CRP is an acute phase protein and is 
elevated significantly in acute rather than chronic vascular disease. 
 
Aspirin reduced serum PDGF levels but only in volunteers; this finding has not been 
reported before and might reflect chance. A reduction in CRP with aspirin was found in 
an earlier study of patients with hypertension 35 but not in studies involving healthy 
subjects.36, 37 Apart from differences in subjects, this positive study involved prolonged 
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treatment over 18 weeks whereas aspirin was given for shorter periods (<1 month) in 
the above two neutral studies and ours. 
 
We found, in secondary analyses, that plasma NOx levels were lower, and vWf levels 
higher, in patients with cerebrovascular disease than in volunteers. Both factors are 
produced by endothelial cells and the results support previous finding that endothelial 
dysfunction is present in patients with vascular disease. For example, patients with 
hypertension, hypercholesterolaemia, diabetes mellitus and previous clinical vascular 
events have lower NOx and elevated vWf levels.38, 39 Similarly, acute stroke is 
associated with low NOx and high vWf levels.18, 40 
 
Although our trials were small, we used a crossover design (thereby allowing each 
subject to act as their own control) which considerably increases statistical power as 
compared with a parallel group design. Additionally, we assessed the effects of 
antiplatelet agents in two different sets of subjects which increases the validity of the 
findings. Importantly, measurements were made by one person who was blinded to 
treatment. 
 
In summary, dipyridamole reduced plasma vWf levels, a measure of endothelial 
dysfunction, in both normal subjects and patients with previous ischaemic stroke. 
Similarly, clopidogrel lowered plasma PAI-1 concentrations in both sets of subjects 
(significantly so in volunteers). The findings suggest that these agents have additional 
effects on non-platelet aspects of atherothrombogenesis, mechanisms which may 
explain, in part, their roles in preventing recurrent vascular events such as stroke. 
The effects of these agents on other vascular risk markers such as fibrinogen and P-
selectin remains to be ascertained.40 
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TABLE 1 
 
Baseline characteristics of subjects. Mean (standard deviation) or frequency (%) 
 
 Normal volunteers Previous ischaemic stroke P 
Number 11 11  
Mean age (year) 39 (8) 62 (10) <0.0001 
Gender, male (%) 8 (73) 6 (55) 0.38 
Hypertension (%) 0 (0) 8 (73) 0.0004 
Diabetes mellitus (%) 0 (0) 0 (0) 1.0 
Smoking (%)   0.03 
   Never 9 (82) 3 (27)  
   Past 1 (9) 5 (45)  
   Current 1 (9) 3 (27)  
Blood pressure (mmHg)    
   Systolic 130 (14) 150 (20) 0.01 
   Diastolic 85 (4) 86 (8) 0.71 
Platelet count (×109.l) 257 (35) 282 (71) 0.31 
Total cholesterol (mmol.l-1) 5.0 (0.7) 5.9 (0.8) 0.01 
LDL-C (mmol.l-1) 3.4 (0.6) 3.8 (0.8) 0.20 
HDL-C (mmol.l-1) 1.0 (0.2) 1.4 (0.4) 0.01 
Triglycerides (mmol.l-1) 1.3 (0.5) 2.2 (1.5) 0.07 
LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol 
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TABLE 2  
Effect of aspirin (A), clopidogrel (C) and dipyridamole (D) on soluble markers; mean difference (standard deviation); p<0.05 in 
bold 
 cGMP (nM) CRP (mg/L) MCP-1 (pg/mL) NOx (µmol/L) PAI-1 (ng/mL) PDGF (ng/mL) vWf (%) 
Volunteers        
  A vs no A 0.30 (0.43) 0.52 (1.05) 9.59 (15.97) -0.06 (0.05) 0.73 (2.20) -3.46 (1.55) 3.48 (4.95) 
  C vs no C -0.27 (0.43) -0.64 (1.05) 4.45 (15.97) 0.02 (0.05) -5.30 (2.20) -1.89 (1.55) 3.16 (4.95) 
  D vs no D -0.55 (0.43) 0.23 (1.05) 1.21 (15.97) -0.001 (0.05) -0.10 (2.20) 1.70 (1.55) -10.01 (4.95) 
Patients        
  A vs no A 0.39 (0.57) 0.06 (0.47) 9.02 (10.50) -0.04 (0.06) -3.77 (2.75) 0.44 (1.98) 2.90 (4.34) 
  C vs no C 0.59 (0.57) 0.05 (0.47) 16.97 (10.50) 0.04 (0.06) -3.61 (2.75) 0.72 (1.98) 1.88 (4.34) 
  D vs no D -0.28 (0.57) -0.96 (0.47) -0.64 (10.50) -0.03 (0.06) 0.42 (2.75) -0.71 (1.98) -10.11 (4.34) 
cGMP: cyclic guanylate monophosphate; CRP: c-reactive protein; MCP-1: macrophage chemoattractant peptide; NOx: nitric oxide 
metabolites; PAI-1: plasminogen activator inhibitor-1; PDGF: platelet derived growth factor; vWf: von Willebrand factor 
Page 15 of 15  
TABLE 3 
Effect of aspirin (A), clopidogrel (C) and dipyridamole (D) on soluble markers in normal volunteers and patients with previous 
ischaemic stroke: mean (standard deviation), *p<0.05 ACD versus other therapies, $p<0.05 volunteers versus patients 
 A C D AC AD CD ACD 
Volunteers        
  cGMP (nmol/L) 2.9 (3.4) 1.6 (1.3) 2.5 (2.1) 3.2 (2.8) 1.8 (2.0) 2.1 (2.5) 1.7 (1.7) 
  CRP (mg/L) 3.7 (6.3) 2.5 (2.8) 4.0 (6.5) 2.3 (2.0) 2.3 (2.8) 1.5 (1.0) 4.4 (6.9) 
  MCP-1 (pg/mL) 242 (123) 211 (81) 240 (115) 260 (137) 249 (102) 247 (107) 242 (90) 
  NOx (µmol/L)) 0.72 (0.17) 0.95 (0.42) 0.83 (0.28) 0.83 (0.31) 0.91 (0.24) 0.81 (0.25) 0.77 (0.19) 
  PAI-1 (ng/mL) 32.1 (17.9) 25.2 (19.1) 29.7 (21.6) 23.4 (14.8) 27.8 (15.6) 24.4 (11.5) 25.3 (13.9) 
  PDGF (ng/mL) 21.5 (11.3) 23.8 (14.8) 25.6 (13.1) 20.8 (17.0) 24.4 (18.0) 23.9 (17.1) 18.8 (12.7) 
  vWf (%) 47.3 (46.4) 56.3 (35.0) 42.2 (18.4) 62.2 (37.7)* 53.7 (29.6) 44.2 (31.8) 40.9 (18.8) 
Patients        
  cGMP (nmol/L) 2.6 (3.4) 2.6 (2.9) 1.3 (1.9) 2.0 (3.2) 1.9 (2.4) 2.2 (2.5) 3.2 (2.8) 
  CRP (mg/L) 4.3 (4.6) 4.3 (3.1) 2.9 (2.6) 3.6 (2.2) 3.3 (2.6) 3.3 (2.9) 2.9 (2.3) 
  MCP-1 (pg/ml) 181 (49) 202 (54) 175 (49) 205 (43) 202 (61) 195 (42) 210 (49) 
  NOx (µmol/L) 0.35 (0.16) $ 0.38 (0.25) 0.34 (0.21) 0.36 (0.29) 0.28 (0.18) 0.38 (0.41) 0.34 (0.27) 
  PAI-1 (ng/mL) 36.7 (19.6) 34.3 (14.6) 37.8 (20.2) 29.5 (19.8) 32.8 (20.6) 35.5 (16.6) 29.5 (13.3) 
  PDGF (ng/mL) 22.8 (17.8) 21.7 (18.1) 22.0 (15.9) 22.7 (18.5) 19.9 (11.3) 21.5 (19.1) 23.3 (13.3) 
  vWf (%) 90.4 (31.0)$ 89.9 (38.4) 81.6 (32.3) 96.7 (41.1)* 84.5 (36.8) 83.2 (46.2) 79.7 (31.0) 
cGMP: cyclic guanylate monophosphate; CRP: c-reactive protein; MCP-1: macrophage chemoattractant peptide; NOx: nitric oxide 
metabolites; PAI-1: plasminogen activator inhibitor-1; PDGF: platelet derived growth factor; vWf: von Willebrand factor 
 
